Related Experiment Video
Updated: Aug 26, 2026
Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
Rapid diagnosis of invasive aspergillosis by antigen detection
1MiraVista Diagnostics and MiraBella Technologies Indianapolis, Indiana 46241, USA. jwheat@miravistalabs.com
Abstract:
Aspergillosis is a serious and often fatal infection in the bone marrow or organ transplant patient, for which improved methods of diagnosis are desperately needed. Currently, the diagnosis is most often made based on clinical findings and radiographic findings, which are nonspecific, and toxic therapies are initiated empirically, often without ever establishing the diagnosis. Without a definitive diagnosis, physicians often withhold or reduce the doses of the antifungal agent when toxicity develops or the patient improves, permitting progression of disease in those with invasive aspergillosis. The Platelia Aspergillus galactomannan antigenemia assay may assist physicians in making these decisions. With a sensitivity of 81% and a specificity of 89% in the studies leading to its FDA clearance, physicians still must be aware of the potential for false-positive and false-negative results; the test does not replace careful microbiological and clinical evaluation. This report will review the relevant literature and provide guidelines for use of the test in patient management.
Insights
Diagnosing invasive aspergillosis in transplant patients is challenging. The Platelia Aspergillus galactomannan antigenemia assay aids diagnosis but requires careful clinical correlation due to potential false results.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Transplant Medicine
Background:
- Aspergillosis poses a significant mortality risk in immunocompromised patients, particularly bone marrow and organ transplant recipients.
- Current diagnostic methods rely on nonspecific clinical and radiographic findings, often leading to empirical and potentially delayed treatment.
- Accurate and timely diagnosis is crucial to guide appropriate antifungal therapy and improve patient outcomes.
Purpose of the Study:
- To review the literature on the Platelia Aspergillus galactomannan antigenemia assay.
- To provide guidelines for the use of this assay in managing patients at risk for invasive aspergillosis.
- To highlight the assay's role in clinical decision-making for transplant patients.
Main Methods:
- Review of relevant scientific literature.
- Analysis of diagnostic performance data (sensitivity and specificity) from studies supporting FDA clearance.
- Clinical case scenario evaluation for assay integration.
Main Results:
- The Platelia Aspergillus galactomannan assay demonstrates 81% sensitivity and 89% specificity.
- The assay can assist in clinical decision-making regarding antifungal therapy initiation and adjustment.
- Awareness of potential false-positive and false-negative results is essential for accurate interpretation.
Conclusions:
- The galactomannan antigenemia assay is a valuable tool in the diagnostic armamentarium for invasive aspergillosis.
- It should be used in conjunction with, not as a replacement for, thorough clinical and microbiological evaluations.
- Guidelines for assay utilization can optimize patient management and improve outcomes in high-risk populations.
